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Histone acetylation is a major mechanism of chromatin remodeling, contributing to
epigenetic regulation of gene transcription. Histone deacetylases (HDACs) are involved
in both physiological and pathological conditions by regulating the status of histone
acetylation. Although histone deacetylase 4 (HDAC4), a member of the HDAC family,
may lack HDAC activity, it is actively involved in regulating the transcription of genes
involved in synaptic plasticity, neuronal survival, and neurodevelopment by interacting
with transcription factors, signal transduction molecules and HDAC3, another member
of the HDAC family. HDAC4 is highly expressed in brain and its homeostasis is crucial
for the maintenance of cognitive function. Accumulated evidence shows that HDAC4
expression is dysregulated in several brain disorders, including neurodegenerative
diseases and mental disorders. Moreover, cognitive impairment is a characteristic
feature of these diseases. It indicates that aberrant HDAC4 expression plays a pivotal
role in cognitive impairment of these disorders. This review aims to describe the
current understanding of HDAC4’s role in the maintenance of cognitive function and its
dysregulation in neurodegenerative diseases and mental disorders, discuss underlying
molecular mechanisms, and provide an outlook into targeting HDAC4 as a potential
therapeutic approach to rescue cognitive impairment in these diseases.
Keywords: HDAC4, cognitive function, cognitive impairment, neurodegenerative diseases, mental disorders
INTRODUCTION
Histone deacetylases (HDACs), accompanying with histone acetyltransferases (HATs), are
implicated in chromatin remodeling and subsequent transcription regulation by controlling the
status of histone acetylation. Histone acetylation makes chromatin conformation more relaxed,
facilitating gene transcription, whereas histone deacetylation induces a condensed chromatin
conformation repressing gene transcription. By controlling the status of histone acetylation,
HDACs are involved in diverse physiological and pathological processes. Moreover, the function
of HDACs is not limited to the histone deacetylation. Recent evidences suggest that HDACs may
also contribute to the deacetylation of non-histone proteins (Lardenoije et al., 2015). In addition,
HDACs also have deacetylase-independent functions, such as histone deacetylase 4 (HDAC4)
(Lardenoije et al., 2015; Han et al., 2016).
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HDAC4 is highly expressed in brain (Grozinger et al., 1999;
Bolger and Yao, 2005; Darcy et al., 2010). It plays a key role in the
maintenance of cognitive function and its alteration is associated
with cognitive impairment in both age-related neurodegenerative
diseases (e.g., Alzheimer’s disease, AD) and development-related
mental disorders (e.g., autism). Therefore, the role of HDAC4
in cognitive function, its dysregulation in cognitive impairment-
related neurodegenerative diseases and mental disorders, and
underlying mechanisms are discussed in this review.
HDAC4 and HDACs
HDACs Classification
Eighteen human HDACs are identified and classed into four
groups based on their homology to yeast HDACs (Didonna
and Opal, 2015). Class I HDACs, consisting of HDAC1, 2, 3,
and 8, are homologous to yeast RPD3 while class II HDACs
have high identity to yeast HDA1, consisting of HDAC4,
5, 6, 7, 9, and 10. According to the protein structure and
motif organization, class II HDACs are further divided into
two subclasses, class IIa with HDAC4, 5, 7, and 9, and
class IIb with HDAC6 and 10. Class III HDACs, named
sirtuins, including SIRT1-7, are homologous to yeast SIR2.
Compared with zinc-dependent HDACs of class I and class II,
class III HDACs are nicotinamide-adenine-dinucleotide (NAD)-
dependent. HDAC11 is the only member of Class IV, which is also
a Zn-dependent HDAC.
The HDAC4 Gene and Protein
The human HDAC4 gene, located on chromosome 2q37.3,
spans approximately 353,480 bp encoding HDAC4 protein
with 1084 amino acids. HDAC4 shuttles between cytoplasm
and nucleus depending on signal transduction-related
phosphorylation status of HDAC4 (Mielcarek et al., 2013).
Normally, phosphorylated HDAC4 retains in the cytoplasm,
while dephosphorylated HDAC4 is imported into the nucleus
(Nishino et al., 2008).
Histone deacetylase 4 protein consists of a long N-terminal
domain and a highly conserved C-terminal catalytic domain.
The deacetylase activity of HDAC4 is almost undetectable
although it has a conserved C-terminal catalytic domain, which
might be caused by a substitution of tyrosine to histidine
in the enzyme active site (Lahm et al., 2007). However,
HDAC4 does play an important role in the regulation of
gene transcription via different ways (Figure 1). First, HDAC4
interacts with multiple transcriptional factors [e.g., myocyte
enhancer 2 (MEF2), runt related transcription factor 2 (Runx2),
serum response factor (SRF), heterochromatin protein 1(HP1),
nuclear factor kappa B (NF-κB)] regulating gene transcription
(Sando et al., 2012; Ronan et al., 2013). Although HDAC4
per se lacks deacetylase activity, it may be involved in histone
deacetylation-mediated transcriptional regulation via interacting
with HDAC3, another member of the HDAC family with
deacetylase activity (Grozinger et al., 1999; Lee et al., 2015). For
example, Lee et al. (2015) showed that HDAC4 is crucial for
HDAC3-mediated deacetylation of mineralocorticoid receptor,
which could be inhibited by class I HDAC inhibitor but not
class II HDAC inhibitor, indicating that HDAC4 is implicated
in protein deacetylation via the deacetylase activity of HDAC3.
Moreover, the deacetylase activity of HDAC4 needs to be further
investigated by multiple approaches as it is not convincing
by the in vitro assay from one study (Lahm et al., 2007).
As the nuclear localization of HDAC4 is regulated by its
interaction with14-3-3, it is possible that the alteration of nuclear
HDAC4 mediated by tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein (14-3-3) is involved in
transcriptional regulation by its deacetylase activity (Nishino
et al., 2008). A recent study suggests that HDAC4 may function
to regulate protein SUMOylation via interacting with SUMO-
conjugating enzyme Ubc9 (Ubc9), a SUMO E2-conjugating
enzyme, contributing to memory formation (Figure 1) (Schwartz
et al., 2016).
FIGURE 1 | Histone deacetylase 4 (HDAC4) in cognitive function and molecular mechanisms. HDAC4 is a global regulator of the transcription of genes
involved in synaptic plasticity, neuronal survival, and neurodevelopment by interacting with multiple proteins, which is essential for the maintenance of normal
cognitive function. Moreover, HDAC4 may function to regulate protein SUMOylation via interacting with Ubc9 contributing to the maintenance of cognitive function.
Solid line and dash line represent confirmed and possible mechanisms, respectively.
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HDAC4 IN COGNITIVE FUNCTION AND
MOLECULAR MECHANISMS
A growing body of evidence indicates that the homeostasis of
HDAC4is crucial for the maintenance of cognitive function by
regulating genes involved in synaptic plasticity, neuronal survival
and neurodevelopment (Figure 1) (Schwartz et al., 2016).
HDAC4 and Synaptic Plasticity
Histone deacetylase 4 interacts with multiple transcription factors
(e.g., MEF2, Runx2, SRF, HP1), 14-3-3, HDAC3 etc. regulating
the transcription of genes involved in synaptogenesis, synaptic
plasticity and neurodevelopment, such as activity regulated
cytoskeleton associated protein (Arc) and protocadherin
(Pcdh10) (Figure 1) (Grozinger et al., 1999; Sando et al., 2012;
Ronan et al., 2013; Rashid et al., 2014; Lee et al., 2015; Sharma
et al., 2015; Krishna et al., 2016; Nott et al., 2016). First, nuclear
HDAC4 represses the expression of constituents of synapses
leading to the impairment of synaptic architecture and strength
in mice (Sando et al., 2012). In addition, mice carrying a
gain-of-function nuclear HDAC4 mutant exhibit deficits in
neurotransmission, learning and memory (Sando et al., 2012).
On the other hand, silencing HDAC4 expression does result in
the impairment of synaptic plasticity, and learning and memory
deficits in both mice and Drosophila (Kim et al., 2012; Fitzsimons
et al., 2013). A proteomics analysis indicates that HDAC4 is
a regulator of proteins involved in neuronal excitability and
synaptic plasticity, which are differentially expressed in normal
aging subjects and AD patients and associated with memory
status (Neuner et al., 2016). A recent study showed that HDAC4
interacts with Ubc9 during memory formation, while the
reduction of Ubc9 in adult brain of Drosophila impairs long-
term memory, suggesting that the role of HDAC4 in memory
formation may be associated with the regulation of protein
SUMOylation (Figure 1) (Schwartz et al., 2016).
Above evidence suggests that HDAC4 homeostasis is crucial
for the maintenance of synaptic plasticity and cognitive function,
i.e., both HDAC4 elevation and reduction lead to cognitive
deficits. It is not surprised that both up-regulation and down-
regulation of HDAC4 impairs synaptic plasticity and memory
function as previous studies have demonstrated that a number
of molecules play a dual role in synaptic plasticity and memory
function. For example, both overexpression and disruption of
regulator of calcineurin 1 (RCAN1) leads to synaptic impairment
and memory deficits in Drosophila and mice (Chang et al.,
2003; Hoeffer et al., 2007; Chang and Min, 2009; Martin
et al., 2012). Moreover, the bidirectional alterations of HDAC4
may differentially disrupt the balance between HDAC4 and its
interacting partners leading to synaptic impairment and memory
deficits as HDAC4 is implicated in multiple signaling pathways by
interacting with many functional proteins (Figure 1). However,
the underlying mechanisms need to be further investigated.
HDAC4 and Apoptosis
Neuronal apoptosis is a major mechanism linking to cognitive
deficits. In addition to synaptic plasticity, HDAC4 is also
involved in neuronal apoptosis. For example, HDAC4 interacts
with NF-κB repressing proapoptotic gene expression, and it
also inhibit ER stress-induced apoptosis by interacting with
activating transcription factor 4 (ATF4), a key transcriptional
factor in ER stress response (Figure 1) (Zhang et al., 2014;
Vallabhapurapu et al., 2015). Moreover, Majdzadeh et al.
(2008) showed that HDAC4 overexpression protects mouse
cerebellar granule neurons (CGNs) from apoptosis by inhibiting
cyclin dependent kinase 1 (CDK1) activity. Consistently,
upregulation of HDAC4 by a NMDAR antagonist protects mouse
hippocampal neurons from naturally occurring neuronal death,
whereas HDAC4 reduction promotes neuronal apoptosis during
development (Chen and Cepko, 2009). Sando et al. (2012)
further demonstrated that HDAC4-C-terminal is crucial for
rescuing HDAC4 knockdown-induced cell death and reduction
of synaptic strength in mouse brains. However, Bolger and Yao
(2005) showed that increased expression of nuclear-localized
HDAC4 promotes neuronal apoptosis in mouse CGNs, while
down-regulation of HDAC4 protects neurons from stress-
induced apoptosis. The conflicting results may be caused by
different cell types and culture conditions. Majdzadeh et al. (2008)
cultured CGNs for 4−5 days before transfection, while Bolger
and Yao (2005) transfected CGNs immediately after cell isolation.
Although CGNs were used in both studies, the maturation status
of neurons when they were transfected may have significant
effects on the conflict results. Moreover, short-term and long-
term protein overexpression may have opposite effects. For
example, a previous study showed that RCAN1 plays an opposite
role in neuronal apoptosis at different culture stages, which may
be associated with aging or maturation processes (Wu and Song,
2013).
HDAC4 and Brain Development
Histone deacetylase 4interacts with multiple transcriptional
factors, repressing the transcription of genes involved in
neurodevelopment (Figure 1) (Sando et al., 2012; Ronan
et al., 2013). Moreover, HDAC4 may be implicated in
neurodevelopment via interacting with HDAC3 which is
necessary for brain development (Norwood et al., 2014). In
human, both HDAC4 deletion and duplication lead to mental
retardation and intelligence disability, suggesting that HDAC4
plays an important role in neurodevelopment which directly links
to cognitive function (Shim et al., 2014).
ABERRANT HDAC4
EXPRESSION/LOCALIZATION IN
NEURODEGENERATIVE DISEASES
Cognitive decline, in particular, learning and memory deficits, is
a characteristic of neurodegenerative diseases [e.g., Alzheimer’s
disease (AD), Huntington’s disease (HD), and Parkinson’s disease
(PD)] which are associated with synaptic dysfunction and
synaptic and neuronal loss. A large body of evidence indicates
that aberrant HDAC4 expression and subcellular distribution
may contribute to the cognitive decline in patients with
neurodegenerative diseases (Table 1). First, increased HDAC4
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TABLE 1 | The alteration of histone deacetylase 4 (HDAC4) in cognitive-related disorders.
Disease Subject tHDAC4 nHDAC4 cHDAC4 Beneficial effects DNA Reference
AD Human Up Shen et al., 2016
AD Mouse Up Anderson et al., 2015
AD Mouse Up Sen et al., 2015
FTLD Human Up Whitehouse et al., 2015
HD Mouse No Down Mielcarek et al., 2013
HD Mouse Down Quinti et al., 2010
ATM Mouse Up Li et al., 2012
ASD Human Up∗ Nardone et al., 2014
BDMR Human Mutation Williams et al., 2010
Depression Human Up∗ Hobara et al., 2010
Depression Mouse Up∗ Sarkar et al., 2014
Depression Mouse Up∗ Sailaja et al., 2012
Schizophrenia Human No∗ Sharma et al., 2008
Schizophrenia Human SNP Kim et al., 2010
tHDAC4, total HDAC4; nHDAC4, nuclear HDAC4; cHDAC4, cytoplasmic HDAC4; no, no change; ∗, mRNA.
expression was observed in prefrontal cortex of aged individuals,
while aging is the major risk factor of neurodegenerative
disorders (Sharma et al., 2008). In addition, a more recent study
showed that HDAC4 is a global regulator of memory deficits
with age (Neuner et al., 2016). Moreover, HDAC4 is involved
in the regulation of SIRT1 which is implicated in both aging
and memory process in rats (Sasaki et al., 2006; Sommer et al.,
2006; Quintas et al., 2012; Han et al., 2016). Furthermore, as
mentioned in the section 2.1, HDAC4 homeostasis is crucial
for the maintenance of cognitive function, i.e., both HDAC4
elevation and reduction lead to cognitive deficits.
HDAC4 in Alzheimer’s Disease
Alzheimer’s disease is the most common form of
neurodegenerative disorders in the elderly leading to dementia.
Progressive memory loss is the clinical characteristics of AD.
Neuritic plaques, neurofibrillary tangles and neuronal loss are
the neuropathological hallmarks of AD. Amyloid β (Aβ) and
phosphorylated microtubule associated protein tau (Tau) are
the major components of neuritic plaques and neurofibrillary
tangles, respectively, while apoptosis is a major mechanism of
neuronal loss (Wu et al., 2014).
The nuclear expression of HDAC4 is markedly increased in
brains of AD patients, while the alteration of total HDAC4,
including both cytoplasmic and nuclear HDAC4, is not
conclusive (Shen et al., 2016). However, the expression of HDAC4
was significantly increased in AD model mice (Anderson et al.,
2015). Moreover, ApoE4, the only confirmed genetic risk factor
of late onset AD, increases nuclear HDAC4 levels compared
with the ApoE3 in transgenic mice (Sen et al., 2015). It suggests
that increased HDAC4 expression or its nuclear localization may
contribute to learning and memory deficits in patients with AD.
HDAC4 in Frontotemporal Lobar
Degeneration
Frontotemporal lobar degeneration (FTLD) is a heterogeneous
neurodegenerative process resulting in frontotemporal dementia.
Progressive difficulties in planning, organizing and language are
the major characteristics of FTLD. The atrophy of frontal and
temporal lobe and inclusions containing abnormal accumulation
of Tau, TAR DNA binding protein (TDP-43) or FUS RNA
bindind protein (FUS) are the characteristic pathological features
of FTLD.
In FTLD patients, cytoplasmic HDAC4 is increased in granule
cells of the dentate gyrus, while HDAC5, the other member of
class IIa HDACs, is not altered, suggesting that HDAC4 may have
a specific role in the pathology of FTLD (Whitehouse et al., 2015).
HDAC4 in Huntington’s disease
Huntington’s disease is a common autosomal dominant
neurodegenerative disease, which is caused by the expansion of
polyglutamine repeats in huntingtin (HTT) protein, named as
mutant HTT (mHTT) (MacDonald et al., 1993; Myers et al.,
1993; Kremer et al., 1994). The characteristic clinical features are
chorea, progressive cognitive decline, and psychiatric symptoms,
while the cognitive problem is often the earliest symptom in
patients with HD (Walker, 2007). mHTT impairs fast axonal
transport, disrupts mitochondrial function and inflammatory
response and promotes apoptosis, which may contribute to the
cognitive decline (Szebenyi et al., 2003; Beal and Ferrante, 2004;
Trushina et al., 2004).
Growing evidence suggests that increased HDAC4 is
implicated in HD pathology, such that reducing HDAC4
expression has beneficial effects. First, overexpression of miR-22
has a protective effect on mHTT model cells, which may be
mediated by HDAC4 reduction as HDAC4 is a target gene of
miR-22 (Jovicic et al., 2013). Second, HDAC4 interacts with
microtubule associated protein 1S (MAP1S) resulting in MAP1S
destabilization and reduction, subsequently suppressing the
clearance of mHTT aggregates and potentiating the toxicity
of mHTT to cultured cells (Yue et al., 2015). Moreover,
HDAC4 is associated with HTT in a polyglutamine-length-
dependent manner and co-localized with cytoplasmic aggregates.
However, reducing HDAC4 expression delays the formation of
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cytoplasmic aggregates, restores BDNF expression, and rescues
synaptic dysfunction in HD mouse models (Mielcarek et al.,
2013). In addition, suberoylanilide hydroxamic acid (SAHA)
promotes HDAC4 degradation, suggesting that reducing HDAC4
expression may contribute to SAHA’s rescue effects on HD model
mice via multiple HDAC4-associated pathways (Figure 1)
(Mielcarek et al., 2011). However, SAHA is also an inhibitor of
class I HDACs and HDAC6, suggesting that its rescue effects may
also be mediated by inhibiting the deacetylase activity of class I
HDACs and HDAC6. Although Quinti et al. (2010) showed that
the reduction of HDAC4 is associated with the progression of
HD in HD model mice, Mielcarek et al. (2013) did not observe
the reduction in same HD model mice. However, they found
that reducing HDAC4 expression has beneficial effects on HD
mice (Mielcarek et al., 2013). As the alteration of HDAC4 in HD
model mice remains inconclusive and it still lacks the evidence
from HD patients, the alteration of HDAC4 in HD and its role in
the pathology of HD need to be further investigated.
HDAC4 in Parkinson Disease
Parkinson disease is the second most common neurodegenerative
disease in the elderly. In addition to tremor, rigidity, gait
disturbances etc. motor dysfunctions, PD patients also have
cognitive impairments (Jankovic, 2008). The major pathological
hallmark of PD is the Lewy bodies which mainly consist
of protein aggregates of a-synuclein, parkin, and ubiquitin
(Jellinger, 2009). In addition, same pathological features were
observed in patients with Lewy body (LB) dementia (Jellinger,
2009).
A couple of studies indicate that HDAC4 is associated with
the pathology of PD. First, mutations in the Parkin gene cause
early onset familial PD and the dysregualtion of parkin has
also been observed in sporadic PD. Second, parkin controls
the levels of sumoylated HDAC4 (Kirsh et al., 2002; Um et al.,
2006). Moreover, HDAC4 co-localized with α-synuclein in the
LB (Takahashi-Fujigasaki and Fujigasaki, 2006). In addition,
paraquat, a widely used herbicide, implicated in the induction
of the pathology of PD, reduces the expression of HDAC4 in
culture cells (Song et al., 2011). Furthermore, previous studies
showed that aberrant HDAC4 expression results in learning and
memory deficits in both mice and Drosophila (Kim et al., 2012;
Fitzsimons et al., 2013). Above evidence suggests that alteration of
HDAC4 may contribute to cognitive decline in patients with PD.
However, no direct evidence shows that HDAC4 is implicated in
the pathology of PD.
HDAC4 in Ataxia-Telangiectasia
Ataxia-telangiectasia (A-T), a rare neurodegenerative disease, is
caused by mutations in the ATM gene. A-T patients showed
many premature aging components, characterized by difficulty
in movement and coordination, and early cognitive impairment
including learning and memory deficits (Vinck et al., 2011; Shiloh
and Lederman, 2016).
In ATM deficient mice, nuclear HDAC4 is increased, which is
mediated by the reduction of ATM-dependent phosphorylation
of protein phosphatase 2A (PP2A). Reduced phosphorylation
of PP2A results in increased HDAC4 dephosphorylation by
enhancing PP2A-HDAC4 interaction (Li et al., 2012). HDAC4
dephosphorylation promotes its nuclear import and subsequent
dysregulation of genes involved in synaptic plasticity, neuronal
survival and neurodevelopment, which may contribute to the
cognitive deficits in ATM mice. Consistently, reduced ATM
accompanying with the increase of nuclear HDAC4 has been
observed in brains of AD patients (Shen et al., 2016).
ABERRANT HDAC4
EXPRESSION/FUNCTION IN MENTAL
DISORDERS
Many mental disorders, including autism spectrum disorders
(ASDs), depression, and schizophrenia, are associated with
neurodevelopment defects and cognitive impairment is a core
feature of mental disorders (Ronan et al., 2013). Increased
evidence indicates that aberrant HDAC4 expression or function
plays an important role in cognitive deficits of mental disorders
(Table 1).
HDAC4 in ASD and BMDR Syndrome
Autism spectrum disorder is characterized by the impairment of
social and communication ability, as well as cognitive defects.
Several lines of evidence suggests that dysregulation of HDAC4
is implicated in ASD (Pinto et al., 2014; Fisch et al., 2016).
First, HDAC4 mRNA was significantly increased in autistic brains
(Nardone et al., 2014). Moreover, ASD, intellectual disability,
developmental delay etc. are the characteristics of Brachydactyly-
mental-retardation (BDMR) syndrome which is caused by 2q37
microdeletion. Importantly, the HDAC4 gene is located in this
small region (Doherty and Lacbawan, 1993–2016). A rare case
of BMDR syndrome carries an inactive mutant of HDAC4,
suggesting that HDAC4 deficiency may be the cause of BMDR
syndrome (Doherty and Lacbawan, 1993–2016; Williams et al.,
2010). Moreover, in patients with BMDR syndrome, HDAC4
modulates the severity of symptoms in a dosage dependent
manner, which further confirms the role of HDAC4 in ASD and
other BMDR features (Morris et al., 2012).
HDAC4 in Depressive Disorders
Depressive disorders are the most common mood disorder
leading to disability, which is characterized by the presence of sad,
empty, or irritable mood and cognitive impairment (Rock et al.,
2014). Recent studies highly suggest that HDAC4 is implicated in
the pathology of depressive disorders. First, aberrant expression
of HDAC4 mRNA has been detected in patients with depression
(Otsuki et al., 2012). Consistently, antidepressant reduces the
recruitment of HDAC4 to the glial cell-derived neurotrophic
factor (GDNF) promoter, consequently increasing the expression
of GDNF which is reduced in patients with depression (Otsuki
et al., 2012; Lin and Tseng, 2015). In patients with bipolar disorder
(BPD), HDAC4 mRNA is significantly increased in a depressive
state, while its expression is marked decreased in a remissive state
(Hobara et al., 2010). In addition, HDAC4 mRNA is significantly
increased in brains of forced-swim stress-induced- and postnatal
fluoxetine-induced depression model mice (Sailaja et al., 2012;
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Sarkar et al., 2014). Intriguingly, adult fluoxetine application does
not induce depression-like behavior in mice which is associated
with unchanged HDAC4 expression. Ectopic overexpression of
HDAC4 in hippocampus is sufficient to induce depression-like
behavior in adult mice, indicating that HDAC4 elevation is the
key to induce depression-like behavior (Sarkar et al., 2014).
Furthermore, depression is a common feature in AD, which may
be associated with the increase of HDAC4 expression in AD
patients.
HDAC4 in Schizophrenia
Schizophrenia is a complex psychiatric disorder, characterized
by impairments in behavior, thought, and emotion. Cognitive
impairment is common in patients with schizophrenia, in
particular, learning and memory deficits. A couple of evidence
suggests that HDAC4 might be associated with the pathology
of schizophrenia. First, one SNP (rs1063639) in the HDAC4
gene associates with the development of schizophrenia in a
Korea population (Kim et al., 2010). Moreover, in patients with
schizophrenia, HDAC4 mRNA is negatively associated with the
expression of GAD67, a candidate gene of schizophrenia (Sharma
et al., 2008). However, the exact role of HDAC4 in the cognitive
deficits of schizophrenia needs to be further investigated.
HDAC4, A SPECIFIC TARGET FOR
COGNITIVE IMPAIRMENT
Growing evidence indicates that HDAC4 is a specific target for
the treatment of cognitive impairment in multiple disorders,
which is different from other HDACs. First, HDAC4 is highly
enriched in brain compared with other HDACs. Second, HDAC4
has no or weak HDAC activity, suggesting that global HDAC
inhibitors, targeting the catalytic sites of HDACs, may have no
effect on HDAC4’s function (Sando et al., 2012). Consistently,
HDAC4 has a different effect on cognitive function compared
with other HDACs. For example, conditional deletion of HDAC4
leads to learning and memory deficits, while global HDACs
inhibition or HDAC2 deficiency significantly improves learning
and memory in mice (Vecsey et al., 2007; Guan et al., 2009; Kim
et al., 2012). Moreover, the maintenance of HDAC4 homeostasis
is crucial for the disease treatment as either increased or
decreased HDAC4 expression is detrimental to the cognitive
function. It suggests that HDAC4 is a potential target for the
treatment of cognitive impairment. However, only one selective
HDAC4 inhibitor, tasquinimod, is commercially available, and
its effect on cognitive function has not been explored. Therefore,
specific HDAC4 modulators should be developed and their roles
in cognitive disorders need to be investigated.
CONCLUSION
Although HDAC4 belongs to the family of HDAC, its deacetylase
activity is weak or undetectable. Thus, it remains elusive
whether HDAC4 per se could repress gene transcription by its
HDAC activity (Figure 1). However, HDAC4 could regulate
the transcription of genes involved in synaptic plasticity,
neuronal survival, and neurodevelopment by interacting with
multiple proteins, which is essential for the maintenance of
normal cognitive function (Figure 1). Moreover, HDAC4 may
function to regulate protein SUMOylation via interacting with
Ubc9 contributing to the maintenance of cognitive function
(Figure 1). Moreover, aberrant expression of HDAC4 may be
implicated in the cognitive impairment of neurodegenerative
diseases and mental disorders. Therefore, HDAC4 is a
potential therapeutic target to rescue cognitive deficits in above
disorders.
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